Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005538/en/
“ANCA-associated vasculitis is a rare, systemic disease which can be rapidly fatal if not appropriately & promptly treated. The variable nature of the disease and its course along with challenging side-effects of current treatment options can severely affect subsequent quality of life for patients,” said John Mills, Vice-Chair of Vasculitis UK. “We very much welcome NICE’s decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.”
“NICE’s decision represents a major advancement for the treatment of GPA/MPA in the UK,” said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge. “Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.”
“We are delighted about this recommendation for patients in England, Wales and Northern Ireland living with GPA/MPA”, said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “It means that an underserved patient population will have access to a first in class treatment aiming to meet major unmet medical needs. We look forward to continue working with the National Health Service to ensure access to this important medicine for patients across the UK as quickly as possible.”
MHRA approval and the NICE recommendation were based on findings from a comprehensive development program, culminating in the results from the pivotal phase-III trial (ADVOCATE) in 331 patients with ANCA-associated vasculitis (GPA/MPA) in 20 countries. This randomized, controlled trial assigned patients to either oral Tavneos® (30mg twice daily) or oral prednisolone on a tapering schedule. All patients received induction treatment with cyclophosphamide or rituximab. The study met its primary endpoints of disease remission at week 26, defined as Birmingham Vasculitis Activity Score (BVAS) of 0 at week 26 and not taking glucocorticoids for treatment of ANCA-associated vasculitis in the previous 4 weeks, and sustained remission at both weeks 26 and 52 defined as a BVAS of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 52. Compared to a prednisolone-based regimen, the Tavneos®-based regimen demonstrated non-inferiority in terms of remission at week 26, and superiority in terms of sustained remission at week 52. Serious adverse events (excluding worsening vasculitis) occurred in 37.3% of patients receiving Tavneos® and in 39% of those receiving prednisolone.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com
About GPA and MPA
GPA and MPA are the two main forms of ANCA-associated vasculitis which is a systemic disease in which inappropriate activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney and lung as major targets, and may be fatal if not treated.
Treatment of GPA/MPA consists of courses of potent immuno-suppressants, in combination with high-dose glucocorticoids (steroids) for prolonged periods of time. However, the unmet medical need remains high as these patients face significant risk of complications, both from their disease and adverse effects from medications, including from long-term use of glucocorticoids. Treatment goals are to achieve sustainable remission to reduce vascular damage and preserve organ function while minimizing the side effects of current treatments.
About Tavneos® (avacopan)
Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By blocking this receptor (C5aR1) for the pro-inflammatory complement system fragment, C5a on inflammatory cells such as neutrophils, Tavneos® reduces the ability of those cells to do damage in response to C5a activation. Moreover, Tavneos® selective inhibition of only the C5aR1 is expected to leave the formation of the beneficial C5b-9 complex intact.
Tavneos® was developed by ChemoCentryx, Inc., who is also developing Tavneos® for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted Tavneos® orphan-drug designation for ANCA-associated vasculitis, C3G and atypical hemolytic uremic syndrome. The European Commission has granted orphan medicinal product designation for Tavneos® for the treatment of two forms of ANCA-associated vasculitis: MPA and GPA (formerly known as Wegener's granulomatosis), as well as for C3G.
VFMCRP has a licensing agreement with ChemoCentryx, Inc., to commercialize Tavneos® outside the US.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005538/en/
Contact information
Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Nominates Dana Strong, CBE and Annabelle Yu Long for Election to its Board of Directors19.8.2025 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) announced todaythat Dana Strong, CBE and Annabelle Yu Long have been nominated by its Board of Directors for election as directors at the upcoming annual meeting of stockholders to be held on November 13, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819180715/en/ Courtesy of Ms. Strong Ms. Strong and Ms. Long are globally respected leaders whose careers have been defined by visionary leadership, strategic insight, and strong track records of driving growth and operational excellence at consumer-focused, high-performing companies. Their nominations underscore the company’s commitment to cultivating a board with deep, strategically aligned expertise across digital, operational and turnaround transformations, Asia/Pacific business matters, direct-to-consumer marketing, and technology. “We are pleased to nominate Dana and Annabelle for election to our Board,” said William P. L
FlightSafety International Expands Arizona Presence with New 100,000-Square-Foot Learning Center in Mesa19.8.2025 21:05:00 EEST | Press release
FlightSafety International, a global leader in aviation training, today announced the expansion of its operations in Arizona with the construction of a new 100,000-square-foot Learning Center in Mesa. This expansion is part of FlightSafety’s broader growth strategy, building on the company’s long-standing presence in the state through its Tucson Learning Center, and adds to its growing network of flagship training centers across the U.S. and around the world. The new Mesa facility is designed to meet rising demand for high-quality aviation training and reflects FlightSafety’s continued commitment to advancing aviation safety and preparedness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815816093/en/ Concept rendering, Oculus Inc. Groundbreaking is scheduled for October 2025, with the center expected to open in early 2028. “This expansion is a reflection of FlightSafety’s continued growth and long-term investment in the
Athos Commerce Takes a Step Toward a Unified Platform19.8.2025 20:59:00 EEST | Press release
Athos Commerce today announced the addition of Search Query Price Detection to its site search solution — an enhancement inspired by capabilities from its Klevu portfolio. The company also refreshed the console’s branding from Searchspring to Athos Commerce, aligning the interface with its evolving identity. Search Query Price Detection automatically identifies and interprets price-related search terms (e.g., “under $50”), returning precise results without the need for manual filter rules. At the same time, the console interface now reflects the Athos Commerce brand while maintaining the familiar user experience that retailers rely on. “We’ve said from the start that Athos Commerce will bring the best capabilities from our portfolio into a unified solution for ecommerce professionals,” said Chuck Haling, CEO at Athos Commerce. “This is a clear step in that direction, showing how our combined expertise becomes practical, high-impact solutions that retailers can put to work right now.” P
Ras Al Khaimah, UAE, is Undeniably One of the Fastest-Growing Real Estate Markets in the Middle East: Industry Leaders19.8.2025 19:12:00 EEST | Press release
Ras Al Khaimah is experiencing an unprecedented real estate boom, rapidly emerging as among the most dynamic property markets in the UAE, guided by the forward-looking vision of His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819507313/en/ Guided by a bold strategic vision and a comprehensive master plan, Ras Al Khaimah’s real estate sector is experiencing unprecedented growth, attracting global investors eager to be part of the Emirate’s journey towards sustainable development. (Photo: AETOSWire) The Emirate is shaping its skyline as it builds its resilient, diversified economy, in line with a strategy that centers around sound planning, sustainability, enhancing quality of life and world-class developments. In recent years, property sales and prices have surged in Ras Al Khaimah, driven by a wave of hospitality, commercia
IQM to Integrate Quantum Computer Into Oak Ridge National Laboratory’s HPC Systems19.8.2025 17:42:00 EEST | Press release
The Department of Energy’s Oak Ridge National Laboratory (ORNL) today announced it has selected IQM Radiance as its first-ever purchased on-premises quantum computer to be integrated into high-performance computing (HPC) systems at ORNL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819262096/en/ IQM Radiance, a 20-qubit quantum computer. IQM Radiance 20-qubit quantum computer is based on superconducting technology and aimed at accelerating hybrid quantum-classical application development. The quantum computer will be delivered by the third quarter of 2025 and is upgradeable to higher qubit counts in the future. Acquiring an on-premises IQM Radiance supports ORNL’s mission to work towards seamless, tight integration between quantum computing hardware and HPC infrastructure. ORNL’s teams have been recognised for leading quantum-HPC integration efforts in the research community for years. Today’s announcement follows an ea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom